Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
2.
Curr Heart Fail Rep ; 20(3): 168-178, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37155122

RESUMEN

PURPOSE OF REVIEW: Following cardiac transplantation, patients have an increased risk of developing cardiac allograft vasculopathy and atherosclerotic cardiovascular disease. Therefore, aggressive lipid management is indicated. Some patients do not achieve optimal lipid profiles with statin monotherapy, however, or discontinue statins due to intolerance. In this review, we investigated the use of PCSK9 inhibitors as an alternative treatment for hyperlipidemia following cardiac transplantation. RECENT FINDINGS: Nine published articles were identified that included 110 patients treated with alirocumab or evolocumab after cardiac transplantation. PCSK9 inhibitors were tolerated by all patients, and each study demonstrated an effective reduction of low-density lipoprotein ranging from 40 to 87% decrease from baseline. In our study, the 110 patients from literature review were added to a cohort of 7 similar patients from our institution for combined analysis. This report supports that PCSK9 inhibitors should be considered following cardiac transplantation when conventional medial therapy is not tolerated or ineffective.


Asunto(s)
Enfermedades Cardiovasculares , Insuficiencia Cardíaca , Trasplante de Corazón , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Humanos , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales/farmacología , Enfermedades Cardiovasculares/prevención & control , Insuficiencia Cardíaca/complicaciones , Trasplante de Corazón/efectos adversos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Lípidos , Inhibidores de PCSK9 , Proproteína Convertasa 9 , Estudios Retrospectivos
3.
Heart Lung ; 52: 174-181, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35065843

RESUMEN

Cardiac involvement in Systemic Lupus Erythematosus can present as end stage heart failure necessitating orthotopic heart transplantation. Most transplant centers regard Lupus as a contraindication to transplant due to risk of disease recurrence in the transplanted organ. Limited reports of heart transplant in Lupus exist in the literature. Herein, we aim to report on the successful transplant and long-term survival of a 24-year-old woman with Lupus and biventricular heart failure. Given the rarity of transplant in Lupus, we also conducted a meta-analysis of reported cases in the literature to assess post-transplant outcomes and evaluate immunosuppression strategies. Our case underlines the feasibility of transplant in Lupus patients, outlines a detailed immunosuppression strategy and favorable long-term outcome to guide centers contemplating such transplants. The long-term survival of our patient, together with review of the thirteen previously described cases, supports that orthotopic heart transplantation can be considered in select patients with Systemic Lupus Erythematosus.


Asunto(s)
Insuficiencia Cardíaca , Trasplante de Corazón , Trasplante de Riñón , Lupus Eritematoso Sistémico , Adulto , Femenino , Supervivencia de Injerto , Insuficiencia Cardíaca/etiología , Insuficiencia Cardíaca/cirugía , Humanos , Lupus Eritematoso Sistémico/complicaciones , Adulto Joven
4.
Crit Pathw Cardiol ; 17(4): 184-190, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30418248

RESUMEN

Chest pain can be a challenging complaint to manage in the emergency department. A missed diagnosis can result in significant morbidity or mortality, whereas avoidable testing and hospitalizations can lead to increased health care costs, contribute to hospital crowding, and increase risks to patients. The HEART score is a validated decision aid to identify patients at low risk for acute coronary syndrome who can be safely discharged without admission or objective cardiac testing. In the largest and one of the longest studies to date (N = 31,060; 30 months), we included the HEART score into a larger, newly developed low-risk chest pain decision pathway, using a retrospective observational pre/post study design with the objective of safely lowering admissions. The modified HEART score calculation tool was incorporated in our electronic medical record. A significant increase in discharges of low-risk chest pain patients (relative increase of 21%; p < 0.0001) in the postimplementation period was observed with no significant difference in the rates of major adverse cardiac events between the pre and post periods. There was a decrease in the amount of return admissions for 30 days (4.65% fewer; p = 0.009) and 60 days (3.78% fewer; p = 0.020). No significant difference in length of stay was observed for patients who were ultimately discharged. A 64% decrease in monthly coronary computed tomography angiograms was observed in the post period (p < 0.0001). These findings support the growing consensus in the literature that the adoption of the HEART pathway or similar protocols in emergency departments, including at large and high-volume medical institutions, can substantially benefit patient care and reduce associated health care costs.


Asunto(s)
Dolor en el Pecho/diagnóstico , Toma de Decisiones , Servicio de Urgencia en Hospital/estadística & datos numéricos , Admisión del Paciente/tendencias , Medición de Riesgo/métodos , Triaje/normas , Dolor en el Pecho/terapia , Electrocardiografía , Femenino , Florida , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...